TXTM (ProText Mobility) Ending Cash Position: $0.00 Mil (As of Sep. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ProText Mobility Ending Cash Position?

ProText Mobility TXTM +1.20% Ending Cash Position is $0.00 Mil as of Sep. 2014.

ProText Mobility's Ending Cash Position for the quarter that ended in Sep. 2014 was $0.00 Mil.

ProText Mobility's quarterly Ending Cash Position declined from Mar. 2014 ($0.08 Mil) to Jun. 2014 ($0.01 Mil) and declined from Jun. 2014 ($0.01 Mil) to Sep. 2014 ($0.00 Mil).

ProText Mobility's annual Ending Cash Position declined from Dec. 2011 ($0.00 Mil) to Dec. 2012 ($0.00 Mil) but then stayed the same from Dec. 2012 ($0.00 Mil) to Dec. 2013 ($0.00 Mil).

ProText Mobility Ending Cash Position Related Terms

ProText Mobility Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ProText Mobility's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProText Mobility Ending Cash Position Chart

ProText Mobility Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.06 0.00 0.00 0.00

ProText Mobility Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.08 0.01 0.00

ProText Mobility Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ProText Mobility's Ending Cash Position for the fiscal year that ended in Dec. 2013 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.001+-0.001
=0.00

ProText Mobility's Ending Cash Position for the quarter that ended in Sep. 2014 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.012+-0.011
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
ProText Mobility (TXTM) has a Ending Cash Position of $0.00 Mil as of Sep. 2014. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ProText Mobility and its competitors.
Is ProText Mobility's Ending Cash Position too high?
ProText Mobility's current Ending Cash Position is $0.00 Mil.
How does ProText Mobility's Ending Cash Position compare to DRSV and YPPN?
ProText Mobility's Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ProText Mobility and its competitors. ProText Mobility's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProText Mobility stock overvalued right now?
ProText Mobility (TXTM) has a current Ending Cash Position of $0.00 Mil. The current Ending Cash Position is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ProText Mobility (TXTM), the current Ending Cash Position is $0.00 Mil as of Sep. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProText Mobility Business Description

Address One West Las Olas Boulevard, Suite 500, Fort Lauderdale, FL, USA, 33301
ProText Mobility Inc is a Biotech Company developing a Hemp/CBD-Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes and technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products, all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.